Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide
- PMID: 34725691
- PMCID: PMC8775655
- DOI: 10.1093/cid/ciab859
Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide
Abstract
The global burden of Group B Streptococcus (GBS) was estimated for 2015 prompting inclusion of GBS as a priority in the Global Meningitis Roadmap. New estimates for the year 2020 and a WHO report analysing the full value of GBS maternal vaccines has been launched to advance evidence based decision making for multiple stakeholders. In this first of a 10-article supplement, we discuss the following (1) gaps in evidence and action, (2) new evidence in this supplement, and (3) what actions can be taken now and key research gaps ahead. We call for investment in the research pipeline, notably description, development, and delivery, in order to accelerate progress and address the large burden of GBS for every family in every country.
Keywords: Group B Streptococcus; maternal vaccines; neurodevelopmental impairment; vaccine market shaping; vaccine readiness.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
Comment in
-
Comparison of Neurodevelopmental Outcomes in Children With Group B Streptococcal Sepsis and Meningitis.Clin Infect Dis. 2022 Sep 14;75(5):922-923. doi: 10.1093/cid/ciac318. Clin Infect Dis. 2022. PMID: 35443067 No abstract available.
References
-
- Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team . 4 Million neonatal deaths: When? Where? Why? Lancet 2005; 365:891–900. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
